Suppr超能文献

极度细胞减灭术对恶性腹膜间皮瘤的生存有益吗?

Is extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?

机构信息

Department of Surgical Oncology, Maltepe Medical Park Hospital, İstanbul, Turkey.

Department of Surgical Oncology, Sivas Numune Hospital, Sivas, Turkey.

出版信息

Acta Chir Belg. 2024 Aug;124(4):281-289. doi: 10.1080/00015458.2024.2301806. Epub 2024 Feb 14.

Abstract

INTRODUCTION

Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is required to achieve complete cytoreduction, which is one of the most important prognostic factors. There is limited information in the literature about the contribution of eCRS in patients with MPM. In this study, we aimed to investigate the impact of eCRS on survival and perioperative outcomes.

METHODS

The Department of Surgical Oncology at Cumhuriyet University database was retrospectively reviewed for MPM patients who underwent CRS-HIPEC between January 2004 and December 2018. Patients who underwent CRS-HIPEC were divided into eCRS and less extensive CRS (leCRS) groups. A resection of 5 organs or 3 small bowel anastomoses were defined as eCRS. Both groups were compared regarding survival, demographic information, and perioperative outcomes.

RESULTS

A total of 31 patients were included. eCRS-HIPEC was used in 15 patients. Complete cytoreduction (CC score 0/1) was achieved in all 31 patients. Compared to leCRS, the eCRS group had a longer median length of stay, longer intensive care unit stay, a higher median peritoneal cancer index (PCI), higher intraoperative blood loss, more frequent occurrence of any complication, and a longer operative time (all p values < 0.001). Clavien Dindo 3-4 complications, ASA, and gender were similar in both groups of patients ( > 0.05). It was found that there was no significant difference between the OS of the eCRS and leCRS groups (37.5 vs. 42.8 months,  = 0.895).

CONCLUSIONS

Rates of serious complications and morbidity are similar in patients undergoing eCRS compared to leCRS. In patients with high PCI and multiorgan involvement, complete cytoreduction can be achieved by performing eCRS, and survival results equivalent to those with low PCI can be achieved.

摘要

简介

恶性腹膜间皮瘤(MPM)是一种难以治疗的罕见疾病。细胞减灭术和腹腔热灌注化疗(CRS-HIPEC)是治疗 MPM 的金标准。有时需要进行极端细胞减灭术(eCRS)以实现完全细胞减灭,这是最重要的预后因素之一。文献中关于 eCRS 在 MPM 患者中的作用的信息有限。在这项研究中,我们旨在研究 eCRS 对生存和围手术期结果的影响。

方法

回顾性分析 2004 年 1 月至 2018 年 12 月期间在 Cumhuriyet 大学外科肿瘤学系接受 CRS-HIPEC 的 MPM 患者的数据库。将接受 CRS-HIPEC 的患者分为 eCRS 和较少广泛的 CRS(leCRS)组。切除 5 个器官或 3 个小肠吻合术定义为 eCRS。比较两组患者的生存、人口统计学信息和围手术期结果。

结果

共纳入 31 例患者。15 例患者接受了 eCRS-HIPEC。所有 31 例患者均实现完全细胞减灭(CC 评分 0/1)。与 leCRS 相比,eCRS 组的中位住院时间更长,重症监护病房停留时间更长,中位腹膜癌指数(PCI)更高,术中出血量更多,并发症更频繁,手术时间更长(所有 p 值均<0.001)。Clavien Dindo 3-4 级并发症、ASA 和性别在两组患者中相似(>0.05)。发现 eCRS 和 leCRS 组的 OS 无显著差异(37.5 与 42.8 个月, = 0.895)。

结论

与 leCRS 相比,行 eCRS 的患者严重并发症和发病率的发生率相似。在 PCI 较高且多器官受累的患者中,通过行 eCRS 可实现完全细胞减灭,并且可以获得与 PCI 较低的患者相当的生存结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验